Pfizer plans to apply for marketing approval for heart drug torcetrapib as a single pill, rather than as a combo-drug with Lipitor, according to a company statement. Torcetrapib is being evaluated in clinical trials and is approximately a year and a half from potential approval. Clinical trials show that torcetrapib substantially raises the levels of high-density lipoproteins (HDL), the “good” cholesterol, providing a novel approach to preventing heart attacks and strokes. Analysts p...